The use of ScFv immune phage-display libraries has already shown good results in the development of human therapeutic recombinant antibodies for tumor-targeted therapy EphA2 [29], and in the discovery of ScFv against IL1RAP from a human library [30]. This evidence concerns the gene EPHA2 and neoplasm.